NCT01707264View on ClinicalTrials.gov

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 9, 2016

Study Completion Date

August 9, 2016

Conditions
Primary Amyloidosis
Interventions
DRUG

NEOD001

Monoclonal antibody administered by intravenous infusion every 28 days.

Trial Locations (7)

10065

Memorial Sloan-Kettering Cancer Center, New York

19104

Hospital of the University of Pennsylvania, Philadelphia

48201

Karmanos Cancer Institute, Detroit

55905

Mayo Clinic, Rochester

94305

Stanford University Cancer Center, Palo Alto

02111

Tufts Medical Center, Boston

02118

Boston University School of Medicine, Boston

All Listed Sponsors
lead

Prothena Biosciences Ltd.

INDUSTRY

NCT01707264 - Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | Biotech Hunter | Biotech Hunter